The escalating levels of antimicrobial drug resistance render it indispensable to explore newer drugs with lesser degrees of toxicity and with fewer chances of developing resistance.
Introduction
Antibiotics forever changed the way we treat infectious diseases and are considered as one of our significant arms in fighting microbial infections. However, over the past few decades, the use of antibiotics is becoming increasingly restricted despite the fact that they exist in large numbers 1 . The reason behind such a rapid decline in the market of antibiotics is largely attributed to the emergence of drug resistant microbes, which render some of the broadest spectrum antibiotics ineffective 2 . Moreover, the toxic side effects produced by some antibiotics also reduce their market demand. Anti-microbial drug resistance is a serious global health issue compromising the treatment of various infections, i.e., minor and life-threatening , antipsychotics [10] [11] [12] [13] [14] and anti-inflammatory agents [15] [16] are examples of some classes of medicine that exihibited limited to significant antimicrobial action. 
Drug sample preparation
All the drug sample solutions used in this study were freshly prepared in distilled water at a concentration of 1 mg/ml for antibiotics and 2 mg/ml for all the non-antibiotics.
Testing for antimicrobial activity

Antimicrobial sensitivity test of non-antibiotics and antibiotics
Antimicrobial activity of non-antibiotics i.e., aspirin, methyldopa, 
Antimicrobial sensitivity test of non-antibiotics and antimicrobials in combination
FIC Index determination by checkerboard technique
According to the satisfactory result of synergy found in antimicrobial activity of combined antimicrobial and non- 
Results
The results of zone of inhibition for aspirin, propranolol, methyldopa and fluoxetine are shown in table 1. Neither antimicrobial control nor growth control showed any contamination or growth indicating controlled working environment for all the tests done. From the results, it was found that all the four non-antibiotics tested for antimicrobial activity showed activity against at least one tested microorganism, i.e., E. coli at a concentration of 2mg/ml, whereas fluoxetine showed antimicrobial activity against all tested organisms.
Antimicrobial activity of antibiotics + non-antibiotics combination
The Percentage of an increase in a zone of inhibition, after the drug was used in combination for benzyl penicillin + propranolol and penicillin + fluoxetine was by 19% and 98%, respectively.
Similarly, when fluconazole was combined with propranolol and fluoxetine, percentage of an increase in surface area of zone of inhibition was by 132.7% and 161.6%.
MIC of propranolol, fluoxetine and fluconazole
The MIC value of non-antibiotics fluoxetine, propranolol and fluconazole against C. albicans was found to be 62.5 µg/ml, 5 mg/ml and 12.5 µg/ml, respectively.
FIC index by checkerboard technique
The interaction of the non-antibiotics with antibiotics against test microbial species was determined by the checkerboard method.
The MIC of fluconazole alone was found to be 12.5 µg/ml. results of above two drug combinations were found to be synergistic. 
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+ Indicates presence of microbial growth, -indicates absence of microbial growth
Discussions
Based on the results obtained, it was observed that E. coli which is naturally resistant to many conventional antimicrobial drugs showed the highest degree of susceptibility to all the nonantibiotics. Whereas, C. albicans and S. aureus was found to be susceptible only to fluoxetine.
The order of antimicrobial activity for non-antibiotics against E.
coli can be represented as Fluoxetine> Methlydopa> Aspirin>
Propranolol. The precise mechanism by which these nonantibiotics exert their antimicrobial effects is not yet known. increase in surface area due to the combination was 10.52% for streptomycin and 12.49% for triflupromazine 28 . 
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+ Indicates presence of microbial growth, -indicates absence of microbial growth The exact mechanism by which those drug combinations showed synergistic activity is not known, though it is important to have such information, knowledge on mechanism of action is not required to determine a degree of synergy in our study, because the mass-action law based determination of synergism is mechanism-independent.
Conclusion
The The anti-depressant drug Fluoxetine was observed to possess in vitro antimicrobial activity against all the test microorganisms, i.e., E. coli, S. aureus and C. albicans. Thus, based on the tested spectrum of antimicrobial activity and synergy, the present study suggests that fluoxetine has a promising potential for being developed into an effective antimicrobial agent.
Additional molecular and animal studies are to be performed in future to further confirm our findings and to elucidate the pharmacological basis for the antimicrobial action of fluoxetine.
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